STOP-HF Trial: Higher Endogenous BNP and Cardiovascular Protection in Subjects at Risk for Heart Failure

Valentina Cannone; Mark Ledwidge; Chris Watson; Paul M. McKie; John C. Burnett; Kenneth McDonald

doi:10.1016/j.jacbts.2021.05.001

STOP-HF Trial: Higher Endogenous BNP and Cardiovascular Protection in Subjects at Risk for Heart Failure

Valentina Cannone, Mark Ledwidge, Chris Watson, Paul M. McKie, John C. Burnett, Kenneth McDonald

Cardiovascular Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

B-type natriuretic peptide (BNP) possesses blood-pressure–lowering, antifibrotic, and aldosterone-suppressing properties. In Stage A and B heart failure, the carriers of the minor C allele of the BNP genetic variant rs198389 have higher circulating levels of BNP and are at decreased risk of hypertension, new-onset left ventricular systolic dysfunction, and hospitalization for major adverse cardiovascular events. Future studies are warranted to investigate the role of BNP genetic testing and BNP-based therapy in the prevention of heart failure.

Original language	English (US)
Pages (from-to)	497-504
Number of pages	8
Journal	JACC: Basic to Translational Science
Volume	6
Issue number	6
DOIs	https://doi.org/10.1016/j.jacbts.2021.05.001
State	Published - Jun 2021

Keywords

B-type natriuretic peptide
STOP-HF Trial
heart failure
rs198389
single nucleotide polymorphism

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.jacbts.2021.05.001

Cite this

@article{77c12629ab334293b0b72c3761d048e2,

title = "STOP-HF Trial: Higher Endogenous BNP and Cardiovascular Protection in Subjects at Risk for Heart Failure",

abstract = "B-type natriuretic peptide (BNP) possesses blood-pressure–lowering, antifibrotic, and aldosterone-suppressing properties. In Stage A and B heart failure, the carriers of the minor C allele of the BNP genetic variant rs198389 have higher circulating levels of BNP and are at decreased risk of hypertension, new-onset left ventricular systolic dysfunction, and hospitalization for major adverse cardiovascular events. Future studies are warranted to investigate the role of BNP genetic testing and BNP-based therapy in the prevention of heart failure.",

keywords = "B-type natriuretic peptide, STOP-HF Trial, heart failure, rs198389, single nucleotide polymorphism",

author = "Valentina Cannone and Mark Ledwidge and Chris Watson and McKie, {Paul M.} and Burnett, {John C.} and Kenneth McDonald",

note = "Publisher Copyright: {\textcopyright} 2021 The Authors",

year = "2021",

month = jun,

doi = "10.1016/j.jacbts.2021.05.001",

language = "English (US)",

volume = "6",

pages = "497--504",

journal = "JACC: Basic to Translational Science",

issn = "2452-302X",

publisher = "Elsevier Inc.",

number = "6",

}

TY - JOUR

T1 - STOP-HF Trial

T2 - Higher Endogenous BNP and Cardiovascular Protection in Subjects at Risk for Heart Failure

AU - Cannone, Valentina

AU - Ledwidge, Mark

AU - Watson, Chris

AU - McKie, Paul M.

AU - Burnett, John C.

AU - McDonald, Kenneth

PY - 2021/6

Y1 - 2021/6

N2 - B-type natriuretic peptide (BNP) possesses blood-pressure–lowering, antifibrotic, and aldosterone-suppressing properties. In Stage A and B heart failure, the carriers of the minor C allele of the BNP genetic variant rs198389 have higher circulating levels of BNP and are at decreased risk of hypertension, new-onset left ventricular systolic dysfunction, and hospitalization for major adverse cardiovascular events. Future studies are warranted to investigate the role of BNP genetic testing and BNP-based therapy in the prevention of heart failure.

AB - B-type natriuretic peptide (BNP) possesses blood-pressure–lowering, antifibrotic, and aldosterone-suppressing properties. In Stage A and B heart failure, the carriers of the minor C allele of the BNP genetic variant rs198389 have higher circulating levels of BNP and are at decreased risk of hypertension, new-onset left ventricular systolic dysfunction, and hospitalization for major adverse cardiovascular events. Future studies are warranted to investigate the role of BNP genetic testing and BNP-based therapy in the prevention of heart failure.

KW - B-type natriuretic peptide

KW - STOP-HF Trial

KW - heart failure

KW - rs198389

KW - single nucleotide polymorphism

UR - http://www.scopus.com/inward/record.url?scp=85111090358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85111090358&partnerID=8YFLogxK

U2 - 10.1016/j.jacbts.2021.05.001

DO - 10.1016/j.jacbts.2021.05.001

M3 - Article

AN - SCOPUS:85111090358

SN - 2452-302X

VL - 6

SP - 497

EP - 504

JO - JACC: Basic to Translational Science

JF - JACC: Basic to Translational Science

IS - 6

ER -

STOP-HF Trial: Higher Endogenous BNP and Cardiovascular Protection in Subjects at Risk for Heart Failure

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this